经口机器人手术在早期声门上型喉癌外科治疗中的作用
基于美国国家癌症数据库2010—2019年临床T1-2期声门上型鳞状细胞癌患者,比较经口机器人手术(TORS)、开放部分喉切除术与经口激光显微手术(TLM)的结局。TORS组辅助治疗率最低(28.4% vs TLM 45.0%、开放 38.5%,p<0.001),切缘阳性率低于TLM(16.9% vs 30.5%,p<0.001),30天和90天术后死亡率无差异;TORS组5年生存率高于开放手术(77.8% vs 66.1%,p=0.01),配对分析后差异持续存在。
要点
- TORS组辅助治疗率28.4%,低于TLM的45.0%和开放手术的38.5%(p<0.001)。
- TORS组切缘阳性率16.9%,低于TLM的30.5%(p<0.001)。
- TORS组5年生存率77.8%,高于开放手术的66.1%(p=0.01),配对分析后差异持续存在。
核心结论
- TORS对于合适的早期声门上型鳞状细胞癌患者可能是一种安全有效的手术方式。
研究设计与样本
- 研究纳入美国国家癌症数据库中2010—2019年诊断为临床T1-2期声门上型鳞状细胞癌并接受TORS、开放部分喉切除术或TLM治疗的患者。
主要发现
- TORS组辅助治疗率28.4%,TLM组45.0%,开放手术组38.5%,组间差异p<0.001。
- TORS组切缘阳性率16.9%,低于TLM组的30.5%,p<0.001。
- 30天和90天术后死亡率在各手术方式间无差异。
- TORS组5年生存率77.8%,高于开放手术组的66.1%,p=0.01。
- 配对分析后TORS组与开放手术组的5年生存率差异持续存在。
临床怎么用
- 作者认为,TORS对于合适的早期声门上型鳞状细胞癌患者可能是一种安全有效的手术方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are several options for primary surgical treatment of early-stage supraglottic squamous cell carcinoma (SCC), including transoral robotic surgery (TORS). The purpose of this study was to compare outcomes of TORS to open partial laryngectomy and transoral laser microsurgery (TLM). METHODS: Patients with clinical classification T1-2 supraglottic SCC diagnosed 2010-2019, treated with TORS, open partial laryngectomy, or TLM in the National Cancer Database were selected. RESULTS: One thousand six hundred three patients were included: 17% TORS, 26.5% TLM, 56.5% open. TORS patients had the lowest rates of adjuvant treatment (28.4% vs. TLM: 45.0%, open: 38.5%, p < 0.001), and lower positive margin rates than TLM (16.9% vs. 30.5%, p < 0.001). Thirty-day and ninety-day post-operative mortality did not differ between the approaches. Five-year survival was higher following TORS compared to open surgery (77.8% vs. 66.1%, p = 0.01); this difference persisted following matched-pair analysis. CONCLUSIONS: TORS may be a safe and effective surgical approach for early-stage supraglottic SCC in appropriate patients.
引用
- Papazian MR, Chow MS, Jacobson AS, et al. Role of transoral robotic surgery in surgical treatment of early-stage supraglottic larynx carcinoma. Head Neck. 2023. PMID: 36825894. doi:10.1002/hed.27325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。